First-time generic approvals (November 2006)
Levonorgestrel and ethinyl estradiol tablets, 0.15/0.03 mg (equiv to Seasonale tablets)
Levonorgestrel and ethinyl estradiol tablets, 0.15/0.03 mg (equiv to Seasonale tablets)
WATSON
Topiramate tablets, 25, 100, and 200 mg (equiv to Topamax tablets)
Diltiazem extended-release capsules, 120, 180, 240, 300, 360, and 420 mg (equiv to Tiazac extended-release capsules)
KV PHARMACEUTICAL
Prednicarbate cream, 0.1% (emollient) (equiv to Dermatop emollient cream, 0.1%)
ALTANA
Caffeine citrate injection, 20 mg/mL, packaged in 60 mg/3 mL single-dose vials (equiv to Cafcit injection)
PHARMAFORCE
Caffeine citrate oral solution, 20 mg/mL, packaged in 60 mg/3 mL vials (equiv to Cafcit oral solution)
PHARMAFORCE
Balanced salt solution (sterile irrigation solution) (equiv to BSS sterile irrigating solution)
AKORN
Medicare’s Drug Price Negotiations Could Impact Physician Reimbursement
September 19th 2024When CMS begins negotiations for physician-administered drugs under the Inflation Reduction Act, providers, including those whose services are covered by commercial insurance, could see lowered reimbursement.
Read More
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
